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Available online 8 March 2017Background: Early studies established that certain lipids were lower in acute myeloid leukemia (AML) cells than
normal leukocytes. Because lipids are now known to play an important role in cell signaling and regulation of ho-
meostasis, and are often perturbed in malignancies, we undertook a comprehensive lipidomic survey of plasma
from AML patients at time of diagnosis and also healthy blood donors.
Methods: Plasma lipid proﬁles were measured using three mass spectrometry platforms in 20 AML patients and
20 healthy blood donors. Data were collected on total cholesterol and fatty acids, fatty acid amides, glycerolipids,
phospholipids, sphingolipids, cholesterol esters, coenzyme Q10 and eicosanoids.
Results:We observed a depletion of plasma total fatty acids and cholesterol, but an increase in certain free fatty
acids with the observed decline in sphingolipids, phosphocholines, triglycerides and cholesterol esters probably
driven by enhanced fatty acid oxidation in AML cells. Arachidonic acid and precursorswere elevated in AML, par-
ticularly in patients with high bone marrow (BM) or peripheral blasts and unfavorable prognostic risk. PGF2α
was also elevated, in patients with low BMor peripheral blasts andwith a favorable prognostic risk. A broad pan-
oply of lipid classes is altered in AMLplasma, pointing to disturbances of several lipidmetabolic interconversions,
in particular in relation to blast cell counts and prognostic risk.
Conclusions: These data indicate potential roles played by lipids in AML heterogeneity and disease outcome.
General signiﬁcance: Enhanced catabolism of several lipid classes increases prognostic risk while plasma PGF2α
may be a marker for reduced prognostic risk in AML.
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001 f 81 M1 NPM1mut;
FLT3-ITD
Normal Intermediate
002 m 75 M5 normal Complex
abnormalities
Unfavorable
003 f 70 M1 NPM1mut Normal Favorable
005 m 72 M6 normal Normal Intermediate
007 m 42 M4 normal Monosomy 7 Unfavorable
009 m 70 M0 normal Complex
abnormalities
Unfavorable
011 m 54 M1 normal Trisomies 8, 19 Unfavorable
015 m 59 M5 NPM1mut Normal Favorable
017 m 55 M0 normal Normal Intermediate
022 m 68 M0 NPM1mut;
FLT3-ITD
Normal Intermediate
027 m 59 M6 normal Normal Intermediate
033 m 67 M4 normal Normal Intermediate
040 m 67 M4 normal Normal Intermediate
045 f 65 M1 normal Complex
abnormalities
Unfavorable
046 f 62 M2 NPM1mut Normal Favorable
050 m 49 M0 normal Trisomy 11 Intermediate
051 m 72 M2 CEPBA Normal Favorable
052 m 64 M2 CEPBA Normal Favorable
056 m 62 M1 NPM1mut Normal Favorable
058 m 66 M1 FLT3-ITD Complex
abnormalities
Unfavorable
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Acute myeloid leukemia (AML) is a fatal disease with a heteroge-
neous genomic and cytogenetic proﬁle. While traditional cell signaling
cascades have attracted considerable research interest in an attempt
to understand the pathogenesis of AML and to optimize AML therapy
[1], little is known regarding the role of lipid mediators in AML cell pro-
liferation or in disease prognosis. However, the study of lipid proﬁles
and lipid metabolism in myeloid leukemias such as AML has a long his-
tory. In the 1960s, the lipid content of various normal and abnormal leu-
kocytes was reported, in which total cholesterol, for example, was
signiﬁcantly lower in AML cells than in normal leukocytes [2]. In a single
chronic myelogenous leukemia (CML), total lymphatic cell lipid was al-
most ﬁve-times lower than from corresponding healthy cells. In addi-
tion, the pattern of ether-linked neutral glycerides also differed
considerably between CML and healthy cells [3]. Subsequently, the
lipid composition of AMLmyeloblasts and immature bonemarrowmy-
eloid cells from healthy personswas compared with that of normal ma-
ture human neutrophils. There was a decreased total cholesterol and
cholesterol/phospholipid ratio, with an increased percentage of unsatu-
rated fatty acids, when compared with normal mature neutrophils [4].
Recently, AML patients were reported to display lower HDL cholesterol
than either healthy controls or ALL patients, with lower total cholesterol
and LDL cholesterol seen only inmale AML patients [5]. It thus appeared
that AML cells might display an increased lipid catabolism. A later study
showed that pharmacological inhibition of fatty acid oxidation (FAO)
retarded proliferation of AML cells cultured on a feeder layer of mesen-
chymal stromal cells. The authors proposed that the shift to
nonoxidative fatty acid metabolism, such as generation of ceramide,
may decrease cell survival [6]. Accordingly, FAO may represent a bio-
chemical characteristic of AML proliferation and this was borne out by
a study of the proliferation of AML blasts from 23 patients that was
inhibited by incubation with the non-β-oxidizable fatty acid
tetradecylthioacetic acid [7]. FAO has recently been recognized as a
key component of cancer cells [8].
In order to attempt to understand better the extent of perturbation
of the plasma lipidome in AML, we have conducted a mass spectrome-
try-based lipidomic investigation of AML patients and healthy blood
donor controls. Additionally, we have analyzed certain clinical disease
features at the time of AML diagnosis in relation to eicosanoid lipid me-
diators and their metabolic precursors, to comprehend what role these
may play in the heterogeneity of this disease.
2. Materials and methods
2.1. Patients and samples
All patients gave their written informed consent to the study, which
was conducted according to theWorld Medical Association Declaration
of Helsinki. The study was approved by the ethics committee of Canton
Bern. Peripheral blood was taken from 20 patients in Bern with a diag-
nosis of AML that had been established from a bonemarrow aspiration.
Plasma was prepared by centrifugation and stored at i.e.−20 °C until
analyzed. The demographic and clinical details of the AML patients are
given in Table 1 and histogram distributions (with normal values) for
hematology and blood chemistry are presented in Supplemental Fig. 1.
Patients had a mean age of 64.0 ± 9.2 (±S.D.) and comprised 16
males and 4 females. The French-American-British (FAB) classiﬁcation
[9,10] of the AML patients was four M0, six M1, three M2, three M4,
two M5, and two M6. The AML patients were also characterized by cy-
togenetics and genetic mutation analysis, which permitted prognostic
risk stratiﬁcation into favorable, intermediate, and unfavorable risk
[11]. Healthy control patient EDTA plasmas were taken from the local
blood bank from 20 blood donors from all over Switzerland (10 males
and 10 females, aged 22–68 years). All control samples tested negative
for antibodies and/or antigens for HIV, HCV and HBV and also testednegative for syphilis. All plasma aliquots were stored at i.e. −20 °C
prior to analysis. It should be noted that, although the AML patients
comprised more males and had a greater mean age than the healthy
controls, this was not expected to confound the lipidomic determina-
tions, since it had long been established (see above) that AML patients
have lower cholesterol and fatty acids than expected for their age.
2.2. Gas chromatography–mass spectrometry fatty acid proﬁling
Proﬁles of plasma total (free and esteriﬁed) fatty acids were deter-
mined for 20 AML patients and 20 controls by gas chromatography–
mass spectrometry (GCMS) after conversion to their corresponding
fatty acid methyl esters (FAMEs) as we have previously described [12].
2.3. Ultraperformance liquid chromatography-electrospray ionization-
quadrupole time-of-ﬂight mass spectrometry untargeted lipidomics
An untargeted lipidomic investigation of plasma from 20 AML pa-
tients and 20 controls was conducted using ultraperformance liquid
chromatography-electrospray ionization-quadrupole time-of-ﬂight
mass spectrometry (UPLC-ESI-QTOFMS) by a modiﬁcation of our pub-
lished method [13]. Data were collected in continuum mode and the
raw chromatographic data were imported into Progenesis QI 2.1 soft-
ware (NonlinearDynamics, Newcastle-upon-Tyne, UK) for visualization
of chromatograms as ion intensity maps, chromatogram alignment,
peak picking, deconvolution and normalization. In ESI+ mode, the fol-
lowing adducts were considered when solving empirical formulae
from accurate mass determinations: [M + H]+, [M + Na]+,
[M + NH4]+, [2M + H]+, and [M + H-H2O]+. In ESI- mode, the fol-
lowing adducts were considered: [M-H]- and [M + Cl]-. When two or
more different adducts were aligned, a neutral mass could be deter-
mined. Both up- and down-regulated AML plasma lipidswere identiﬁed
in Progenesis QI by searching various databases, including HMDB,
ChemSpider, and Lipid Maps and reported on the basis of their fold
change from control plasma and their statistical signiﬁcance on the
basis of ANOVA. Matching to database entries was made on the basis
of accurate mass, isotope similarity and retention time.
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quadrupole linear ion-trap mass spectrometry
Patient and control plasmas were analyzed in Leipzig for their con-
centration of seven polyunsaturated fatty acids (PUFAs) and 94 eicosa-
noids using fast liquid chromatography-quadrupole linear ion-trap
mass spectrometry. The assay involved analysis of analytes and deuter-
ated internal standards detected by 123 multiple reaction monitoring
transitions using a 5500QTrapmass spectrometer (AB Sciex, Darmstadt,
Germany) operating in ESI mode and with quantitation performed
against deuterated internal standards as described [14]. The speciﬁc
multiple reaction monitoring transitions employed for 38 eicosanoids
and 10 deuterated internal standards, together with their retention
times, are given in Supplemental Table 1.
2.5. Statistics
Univariate statistical analysis was performed using GraphPad Prism
6.07 (GraphPad Software, Inc., La Jolla, CA). Means are expressed ±S.D.
and p values are all two-sided. Group differences were analyzed
nonparametrically using Kruskal-Wallis for three or more data sets or
the Mann-Whitney U test for two data sets. In order to minimize false
discovery, p values derived from multiple comparisons were subjected
to Dunn's correction. These conservative measures were adopted to
minimize the likelihood that lipid biomarkers for AML arose stochasti-
cally. Multivariate data analysis was conducted using SIMCA 14 (MKS
Umetrics AB, Malmö, Sweden).
3. Results
3.1. Targeted fatty acid lipidomics by GCMS
FAME analysis was conducted by GCMS and yielded fatty acid pro-
ﬁles for combined free and esteriﬁed fatty acids [12,15]. Multivariate
data analysis using SIMCA 14 revealed an almost complete separation
of the 20 AML and 20 control plasmas in both the unsupervised PCAFig. 1.Multivariate data analysis for GCMS lipidomics in AML and control plasmas. A, Unsuperv
respectively. B, Supervised PLS-DA. Red and green symbols represent AML and control plasma s
whereby one-seventh of the data is removed, randomized, returned, and the PLS-DAmodel rebu
Q2 is the predictability (orange symbols). The data are not over-ﬁtted because the permuted va
valid. D, Orthogonal PLS-DA loadings S-plot showing lipid molecules that are upregulated (upp
2 = cholesterol, 3 = 18:0, 4 = 20:4n-6, 5 = 20:3n-6, 6 = 20:2n-6, 7 = 20:5n-3.and supervised PLS-DA models (Fig. 1A,B). A total of nine fatty acids
plus cholesterol were evaluated statistically. The OPLS-DA loadings S-
plot (Fig. 1D) revealed a number of upregulated total fatty acids plus
total cholesterol in AML plasmas versus healthy controls. Two fatty
acids, palmitic (16:0) and oleic (18:1) acids did not differ statistically
between AML and control plasmas (Fig. 2A,C). Several fatty acids
(stearic (18:0), eicosatrienoic (20:3n-6), arachidonic (20:4n-6), and
lignoceric (24:0) acids) displayed a statistically signiﬁcant lower con-
centration in AML plasmas compared to control plasmas (Fig. 2B,F,G,I).
It was previously reported that lignoceric acid and its monounsaturated
derivative nervonic acid ((24:1n-9)) were depressed in AML plasmas
relative to healthy controls, a phenotype sharedwith hepatocellular car-
cinoma [12]. This observation has now been conﬁrmed and presumably
represents increased peroxisomal β-oxidation of very long-chain fatty
acids in AML, reported to be regulated by the peroxisomal membrane
transporter ALDP (ABCD1) [16]. Expression of ABCD1 in leukemias is
currently unknown. Moreover, for linoleic (18:2n-6), eicosadienoic
(20:2n-6), and eicosapentaenoic (20:5n-3) acids, together with choles-
terol, the majority of AML plasmas had virtually undetectable concen-
trations (Fig. 2D,E,H,J). For each of these lipids measured by GCMS
FAME analysis, with the exception of palmitic and oleic acids, the two
most abundant free fatty acids in plasma [17], the AML patients had sta-
tistically signiﬁcantly lower plasma concentrations of total fatty acids
and total cholesterol than controls. These data were also tested for gen-
der differences. None of the following, 14:0, 14:1(11Z), 15:0, 16:0,
16:1(9Z), 18:0, 18:1(9Z), 18:2(9Z,12Z), 18:3(9Z,12Z,15Z), 19:0, 20:0,
20:2(11Z,14Z), 20:3(8Z,11Z,14Z), 20:4(5Z, 8Z,11Z,14Z), 20:5(5Z,
8Z,11Z,14Z,17Z), 22:6(4Z,7Z,10Z,13Z,16Z,19Z) or cholesterol showed
statistically signiﬁcant differences between males and females, neither
for the AML cases nor the controls.
3.2. Untargeted lipidomics by UPLC-ESI-QTOFMS
UPLC-ESI-QTOFMS was used to conduct an untargeted lipidomic in-
vestigation [13] of 20 AML and 20 control plasmas. A total of 50 lipid
molecules from several classes were found to be highly statisticallyised PCA scores plot. Red and green symbols represent AML and control plasma samples,
amples, respectively. C, Validation of the PLS-DAmodel using the leave-one-out procedure
ilt. One hundred such permutationswere used. R2 is the correlation (purple symbols) and
lues for R2 and Q2 fall below 0.3 and zero, respectively, and therefore the PLS-DAmodel is
er right quadrant) and downregulated in AML plasma (lower left quadrant). 1 = 18:2n-6,
Fig. 2.Univariate data analysis for GCMS lipidomics in AML and control plasmas. Red and green symbols represent AML and control plasma samples, respectively. Vertical dotted lines are
median values,with the same color code. p-Values derive from theMann-WhitneyU test. Values are relative concentrations (peak area/internal standard peak area)measuredbyGCMS. A,
palmitic acid (16:0); B, stearic acid (18:0); C, oleic acid (18:1n-9);D, linoleic acid (18:2n-6); E, eicosadienoic acid (20:2n-6); F, eicosatrienoic acid (20:3n-6); G, arachidonic acid (20:4n-6);
H, eicosapentaenoic acid (20:5n-3); I, lignoceric acid (24:0); J, cholesterol.
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controls. The mass errors for their assignments averaged 0.9 ppm. Of
these lipid molecules, 12 were elevated in AML plasma and comprised
ﬁve free fatty acids (palmitic, palmitoleic, oleic, linoleic and arachidonic
acids; 1.5- to 5.2-fold increase), two fatty acid amides (oleamide and
palmitoleoyl ethanolamide; ∞-fold increase), two
lysophosphatidylethanolamines (LPE(18:0) and LPE(20:2); 2.6- to 2.8-
fold increase), and three glycerolipids, comprising a monoacylglycerol
(MG(18:0)), a diacylglycerol (DG(34:1)) and a triacylglycerol (triglyc-
eride; TG(56:5)) that were elevated 1.3- to 2.7-fold (Supplemental
Table 2). The greatest statistical and biological ﬁnding was the appear-
ance of two fatty acid amides (FAAs), oleamide and palmitoleoyl
ethanolamide (POEA), in AML plasma, both of which can be considered
to be endocannabinoids that act on CB1 and CB2 receptors [18,19], with
elevated plasma POEA reported to be associated with certain anxiety
states [19] and oleamide being an important regulator of sleep via the
CB1 receptor [20].
The 38 diminished lipid molecules in AML patient plasma are also
shown in Supplemental Table 2. They fell into six lipid categories, com-
prising two lysophospholipids (LPC(20:2) and LPE(18:2); lowered 2.8-
to 3.2-fold), four triglycerides (TG(51:8), TG(52:8), TG(53:8), andTG(53:9); lowered 2.1- to 2.7-fold), 13 phospholipids (PC(32:0),
PC(36:2), two PC(36:3)s, PC(36:4), PC(36:5), PC(38:3), PC(40:7),
PC(40:8), PC(P-36:4), PE(40:6), PE(44:10), and PS(36:2); lowered 1.4-
to 29.5-fold), 14 sphingolipids (SM(18:1/12:0), SM(18:1/14:0),
SM(18:1/20:0), two SM(18:1/22:1)s, SM(18:1/23:0), SM(18:1/24:1),
SM(18:0/12:0), SM(18:0/22:0), SM(18:0/22:1), SM(18:0/24:0), two
SM(18:0/24:1)s, and Cer(18:1/24:1); lowered 1.3- to 4.8-fold), four
cholesterol esters (cholesterol 3-O-sulfate, CE(18:2), CE(18:3), and
CE(20:3); lowered 1.4- to 2.1-fold), and coenzyme Q10 (CoQ10;
lowered 1.6-fold). This fall in individual plasma triglycerides, phospho-
lipids and cholesterol esters probably contributed to the attenuation of
free and esteriﬁed individual plasma fatty acids and cholesterol ob-
served above.
Selected lipids were tested for gender differences. No statistically
signiﬁcant differences between males and females, neither for the
AML cases nor the controls, were found for these plasma lipids.
3.3. Targeted PUFA and eicosanoid lipidomics by FLC-QqLIT-MS
The targeted determination of PUFAs and their eicosanoid metabo-
lites was conducted using FLC-QqLIT-MS. The MRM procedures used
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tions of PUFAs in the ng/ml range and eicosanoids in the pg/ml range
[14]. This group of lipids comprises many important bioactive lipid me-
diators and their precursors. Because AML is a heterogeneousmalignan-
cy, these lipidomic ﬁndings have been expressed in relation to the
severity of disease, in particular, number of bone marrow (BM) blasts,
number of peripheral blasts, and prognostic risk stratiﬁcation [11]. The
current lipidomic study was of insufﬁcient size to analyze the ﬁndings
in relation to the major Class I\\V gene mutations that co-operate in
AML leukemogenesis [11]. As shown in Supplemental Fig. 4A, the %
BM blasts were divided into intermediate (5–65%) and high (N80%).
Similarly, % peripheral blasts were divided into low (≤10%) and high
(N10%) (Supplemental Fig. 5A). Finally risk stratiﬁcation was based
upon a cytogenetic primary evaluation with genetic mutations provid-
ing secondary information [11,21] (Table 1).
Fig. 3 shows the plasma levels of three PUFAs, three PUFA oxidized
metabolites, and ﬁve prostaglandins, in control subjects and AML pa-
tients fractionated into intermediate and high BMblasts. The arachidon-
ic acid (AA) de novo synthesis pathway from 18:3n-6 via 20:3n-6 was
highly statistically elevated in AML, in particular, in AML with high BM
blasts. Oxidized AA metabolites were also statistically altered in AML,
with 5-HETE elevated, but only in intermediate BM blast patients, 11-
HETE diminished in both intermediate and high BM blast patients, and
15-oxo-ETE diminished in intermediate BM blast patients relative to
controls, with high BM blast patients further diminished relative to in-
termediate BM blast patients. The prostaglandin PGF2α was consider-
ably elevated in plasma from AML patients, 5-fold in intermediate BM
blast patients and 2-fold in high BM blast patients. This demonstrates
that the prostaglandin synthetic cascade, beginning with 18:3n-6 (Fig.
3), was upregulated in AML with a modest relationship to BM blastFig. 3. Lipidmetabolic pathways signiﬁcantly altered in relation to bonemarrow (BM)blasts at d
level in AML patientswith intermediate (5–65%) BMblasts, red bars=plasmametabolite level
blasts see S3A. *means p b 0.05; **means p b 0.01; ***means p b 0.001 for differences from cont
fatty acid elongase; 2,Δ5-desaturase; 3, COX-1 and COX-2; 4, PGE synthase; 5, carbonyl reducta
reaction; 9, spontaneous reaction; 10, prostaglandin D synthase; 11, spontaneous reaction; 12,status. PGF2α is a potent peripheral vasoconstrictor [22]. Moreover,
PGJ2 was diminished in AML plasma, virtually extinguished in high
BM blast patients. PGJ2 has well documented antiproliferative activity,
both in vitro and in vivo [23], potentially explaining the apparent inverse
correlation observed between PGJ2 plasma concentration and % BM
blasts. The PGE2 metabolite 15-keto-PGE2 was also quenched in AML
plasma, both in intermediate and high BM blast patients. 15-Keto-
PGE2 is produced by 15-prostaglandin dehydrogenase (15-PGDH), an
activity present in the HL-60 acute promyelocytic leukemia cell line
[24]. The prostacyclin (PGI2) metabolite 6-keto-PGF2αwas diminished
in intermediate BM blast patients only, but another PGI2 metabolite
6,15-diketo-13,14-dihydro-PGF1αwas highly increased, 5-fold in inter-
mediate BM blast patients and 8-fold in high BM blast patients. Both of
these PGI2metabolites are formed by spontaneous hydrolysis and have
been reported to reduce free and total cholesterol by up to 50% in cul-
tured arterial smooth muscle cells. The extent to which elevated 6,15-
diketo-13,14-dihydro-PGF1α contributes to the fall in plasma choles-
terol in AML (Fig. 2J) is not known. Additional details, together with
othermetabolites, are given in Supplemental Figs. 3 and 4. Furthermore,
Supplemental Fig. 2G establishes statistically signiﬁcant correlations be-
tween ﬁve measured PUFAs and % BM blasts (p=0.005 to 0.025). Sim-
ilar correlations did not hold for any of the eicosanoids measured.
Fig. 4 shows the samemetabolic pathways but in relation to periph-
eral blasts. The pattern is very similar to that seen with BM blasts (Fig.
3). Of particular note are the observations that plasma i.e. 20:4n-6 was
statistically signiﬁcantly elevated in AML patients with high peripheral
blasts (N10%) and plasma PGJ2 is virtually absent from the same pa-
tients. Both these represent oncogenic signals and this is why they
may bemore associated with high BM and peripheral blasts, potentially
involved in leukemogenesis. Interestingly, however, there was noiagnosis. Blue bars=plasmametabolite level in controls, orange bars=plasmametabolite
in AML patients with high (N80%) BMblasts. Error bars represent SD. For distribution of BM
rols. #means p b 0.05 for differences from intermediate BMblasts. Enzymes involved are 1,
se 1; 6, 15-hydroxyprostaglandin dehydrogenase; 7, prostacyclin synthase; 8, spontaneous
5-lipoxygenase; 13, arachidonic acid 11-oxidoreductase; 14, 15-lipoxygenase.
Fig. 4. Lipidmetabolic pathways signiﬁcantly altered in relation to peripheral blasts at diagnosis. Blue bars= plasmametabolite level in controls, orange bars= plasmametabolite level in
AML patients with intermediate (≤10%) peripheral blasts, red bars= plasmametabolite level in AML patients with high (N10%) peripheral blasts. Error bars represent SD. For distribution
of BM blasts see Supplemental Fig. 5A. * means p b 0.05; ** means p b 0.01; *** means p b 0.001 for differences from controls. For key to enzymes, see Fig. 3.
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the patients studied (Supplemental Fig. 5G). Additional details, together
with other metabolites, are given in Supplemental Figs. 5–7.
An analysis was conducted on the PUFA and eicosanoid plasma
levels in relation to prognostic risk stratiﬁcation, whereby AML patients
were classiﬁed as favorable (F), intermediate (I) or unfavorable (U)
prognostic risk based upon cytogenetic and molecular ﬁndings [11]
(Table 1). Their lipid levels were compared, also to controls (C). The re-
lationship between prognostic risk stratiﬁcation and AA synthesis and
metabolism is outlined in Fig. 5. Regarding plasma levels of i.e. 20:4n-
6, interestingly, there was no difference between control and favorable
risk groups, while both intermediate and unfavorable risk groups were
elevated 1.8- to 2-fold (p b 0.001), with unfavorable risk higher than in-
termediate risk (p b 0.05) (Supplemental Fig. 8C). For antiproliferative
PGJ2, unfavorable risk patients displayed a 45-fold reduced plasma
level (p b 0.05) (Supplemental Fig. 9G), congruent with the ﬁndings
for high BM and peripheral blasts (Figs. 3 and 4). Plasma levels of 18
PUFAs and eicosanoids in relation to prognostic risk are shown in Sup-
plemental Figs. 8–10.
Finally, in contrast to the AA canonical eicosanoid cascade, leading to
the metabolites discussed above, data from the parallel pathway
starting with eicosapentaenoic acid (EPA; 20:5n-3) was also collected
(Supplemental Fig. 11C). Plasma concentrations of free EPA in controls
and AML patients were similar (Supplemental Fig. 11A), in contrast to
total (free and esteriﬁed) EPA (Fig. 2H). EPA is converted to thrombox-
ane A3 (TxA3) by COX-1/COX-2 and CYP5A1, and then spontaneously
hydrolyses to TxB3 [1]. This EPAmetabolitewas not detected in AMLpa-
tient plasma, relative to control plasma (Supplemental Fig. 11B). Since
COX-1/COX-2 clearly operate in AML, evidenced by AA metabolites in
AML plasma, it must be assumed that CYP5A1 is deﬁcient in AML.
CYP5A1 is found in platelets [25] and, since the AML patients were
thrombocytopenic, this may explain this ﬁnding.Selected lipids were tested for gender differences. No statistically
signiﬁcant differences between males and females, neither for the
AML cases nor the controls, were found for the following plasma eicos-
anoids: DHGLA [20:3(8Z,11Z,14Z)], arachidonic acid [20:4(5Z,
8Z,11Z,14Z)], EPA [20:5(5Z, 8Z,11Z,14Z,17Z)], 8,9-DHET, 11-dehydro-
TxB2, PGE2/8-isoPGE2, 12-HEPE, 11β-PGE2, 15-keto-PGF2α, 15-keto-
PGE2, 8-iso-15-keto-PGF2α, PGF1α, and PGF2α.
3.4. Summary description of the AML lipidome
The plasma lipidomic landscape of AML is depicted in Fig. 6. Clear
patterns can be seen in the various lipid pools. For example, GCMS
targeted lipidomics (Fig. 2) established that total plasma fatty acids
were depressed and this was consistent with the attenuation of plasma
phosphocholines, triglycerides, and cholesterol esters, rich contributors
to the total fatty acid pool. In contrast, certain free fatty acids, deter-
mined by untargeted UPLC-ESI-QTOFMS lipidomics (Supplemental
Table 2) and targeted FLC-QqLIT-MS lipidomics (Fig. 3), were elevated
in AML plasma, with the exception of mainly dietary derived EPA
(20:5n-3) [26], which was virtually absent from AML plasma, together
with its 12-lipoxygenase metabolite 12-HEPE [27] and its COX-1/COX-
2/CYP5A1 metabolite TxB3 [25]. A range of SMs were also attenuated
in AML plasma (Supplemental Table 2), which could also have contrib-
uted to the decline in total FAs. Additionally, many prostaglandins were
also reduced in AML plasma, including the potent inﬂammatory media-
tors PGE2 and PGF2α. The changes in arachidonic acid de novo synthesis
andmetabolism to prostanoidswas particularly striking in AMLpatients
with high BM and peripheral blasts and in those stratiﬁed as unfavor-
able prognostic risk. LTB4 is formed from AA by the action of 5-
lipoxygenase and promotes a number of leukocyte functions, including
aggregation and chemotaxis. Its principal and less active metabolite is
12-oxo-LTB4, formed by LTB4 12-hydroxydehydrogenase [28]. AML
Fig. 5. Lipid metabolic pathways signiﬁcantly altered in relation to risk stratiﬁcation at diagnosis. Blue bars = plasma metabolite level in controls; green, orange and red bars = good,
intermediate and bad risk, respectively. Error bars represent SD. * means p b 0.05; ** means p b 0.01; *** means p b 0.001 for differences from controls. # means p b 0.05 for differences
from good risk patients. For key to enzymes, see Fig. 3.
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mation of LTB4 in AML, that was observed in vitrowith blast cells from
both AML and CML [29].Fig. 6. TheAML lipidomic landscape. Ten lipid pools are shown. ↑means lipid upregulated inAM
not detected in control plasma. ↓means lipid downregulated in AML plasma. ↓↓↓means lipidm
text.Two FAAs, that are considered to act as endocannabinoids, displayed
anunquantiﬁable increase in AMLplasma, since theywere undetectable
in control plasmas (Supplemental Table 2). Finally, CoQ10, which is a keyL plasma relative to control plasma. ↑↑↑means lipidmassively upregulated in AML plasma,
assively downregulated in AML plasma or not detected in AML plasma. For lipid names see
112 T. Pabst et al. / BBA Clinical 7 (2017) 105–114component of themitochondrial electron transport chain that generates
ATP by aerobic respiration and also a component of serum lipoproteins
[30], was 40% reduced in AML plasma (p= 5.5 × 10−11).
Thus, the landscape of the AML plasma lipidome is one involving a
global reprogramming of lipid biochemistry that involves many of the
major classes of lipids, including highly potent lipid mediators. This
metabolic rewiring displays no gender differences. The implications of
these ﬁndings for AML patients will be hitherto discussed.
4. Discussion
The concept that cancer cells engage in major metabolic
reprogramming is borne out by this lipidomic study of AML plasma. A
major depletion of total fatty acids and cholesterol was observed. This
is remarkable given that the AML patients were older than the controls
with a greater proportion of males. Had it been possible to obtain truly
age- and sex-matched controls, it is very likely that these differences
would have been even greater. These observation are consistent with
earlier reports [2–5] that lead to the conclusion that AML cells may dis-
play elevated lipid catabolic rates, including FAO, a process now recog-
nized as a key component of cancer cells [8]. CT2 (SLC22A16) is a
plasma membrane carnitine transporter that is over expressed in AML
cells relative to normal hematopoietic cells fromhealthy subjects. Carni-
tine is required for the transport of fatty acids into the mitochondrion
for FAO [31]. Knockdownof CT2with shRNA reduced the growth and vi-
ability of AML cells, suggesting that CT2 and therefore FAO,may be a tar-
get for AML treatment [31]. The observations reported here ofmassively
reduced total fatty acid plasma concentrations supports the essential
role of FAO in AML. Because FAO feeds the Krebs cycle with abundant
acetyl-CoA, increased amounts of citrate will be generated, which is
the starting point for de novo fatty acid synthesis for new membrane
components [32]. This represents a “futile metabolic cycle” of fatty
acid synthesis and breakdown, suggested to be a hallmark of cancer
cell metabolism [8]. Breaking this cycle has been seen as a means to de-
velop novel therapeutic strategies against AML, for example, by blocking
the rate limiting enzyme of FAO, carnitine palmitoyl transferase 1a
(CPT1a), with the inhibitor ST1326 [33]. Clearly, understanding in vivo
lipid homeostasis in AML patients may assist in the development of
new drug targets and therapies.
The observed decline in sphingolipids, phosphocholines, triglycer-
ides and cholesterol esters in AML plasma relative to controls may be
driven by the enhanced rates of FAO in AML cells. Further work will
be required to examine the discretemechanisms involved in these phe-
nomena within AML blasts, but this falls beyond the scope of this pro-
ject. However, it is of interest to note that, although the AML patients
were signiﬁcantly older, with more males, than the blood donor con-
trols recruited, they, counterintuitively, had lower plasma lipids, includ-
ing total cholesterol and total fatty acids. As stated earlier, had the two
groups been age- and sex-matched, the plasma lipid differences
would have been expected to be even greater than reported here.
Two fatty acyl amides (FAAs), oleamide and POEA, were detected in
AML plasma but were not detected in any control plasma. Oleamide is a
sleep regulator via the CB1 receptor [20] and POEA has been implicated
in anxiety disorders seen in abstinent cocaine addicts [19]. The appear-
ance of these endocannabinoid-like FAAs in AML plasma may be re-
sponsible for some of the symptoms experienced by AML patients,
such as lethargy and loss of appetite. Moreover, it has been reported
that both pediatric [34] and adult [35] AML patients can develop hyper-
glycemia. The endocannabinoid system,which can also promote hyper-
glycemia [36,37] warrants further investigation in AML.
The reduction in CoQ10 plasma concentration in AMLmay be of rel-
evance. Chemical inhibition of CoQ10 in AML HL-60 cells led to in-
creased cellular levels of superoxide [30]. It is unclear the extent to
which plasma CoQ10 concentrations reﬂect cellular levels and to what
degree CoQ10 protects against apoptosis of AML cells as it does for
cells in culture [38]. Little literature exists for CoQ10 in AML.The ﬁnding reported here that are most relevant to the biology of
AML are the differential levels in AML and control plasma of the mea-
sured PUFAs and their eicosanoidmetabolites. Although AA is principal-
ly produced by the action of sPLA2 and cPLA2 on plasma membrane
phospholipids [39], which release preformed AA into the cytosol, it
may also be synthesized de novo from18:2n-6 by the action of elongases
and desaturases [40]. Both AA and its precursors 18:3n-6 and 20:3n-6
were elevated in AML plasma. The association of prominent AA concen-
trations in AML plasmaparticularlywith high BMblasts, high peripheral
blasts and both intermediate and unfavorable prognostic risk patients
may reﬂect the importance of the AA cascade in AML. Interestingly,
AML cells express a reduced capacity for stimulated release of AA that
is unrelated to cPLA2 [41]. This may switch AA production towards de
novo synthesis, as observed here. AA is the precursor of many biological
mediators, including prostaglandins, prostacyclin, thromboxanes, leu-
kotrienes and hepoxilins. Variousmembers of these groupswere deter-
mined in this study. Of potential importance was the observation that
PGF2α was elevated, in particular in relation to AML with low BM and
peripheral blast and with a favorable prognostic risk. Early studies re-
ported that, at low concentration, PGF2α had stimulatory effects upon
cultured mouse leukemia lymphoblasts, but at higher concentrations,
PGF2α was inhibitory [42]. In addition, mouse myeloid leukemia cells
were inhibited by PGF2α from differentiating into macrophages and
granulocytes on stimulation with various inducers [43]. These observa-
tionswould be consistentwith theﬁndings reported here. Evidencewas
obtained that 15-hydroxyprostaglandin dehydrogenase (NAD+) (15-
PGDH; EC 1.1.1.141) activity was downregulated in AML, due to the
massively reduced plasma levels of 15-keto-PGE2, which was detected
in only 1/20 AML plasma samples. HL-60 cells have been reported to
possess this metabolic activity with respect to PGE2 and 15-HETE [44].
Both of these activities in vivowere observed in this study to be dimin-
ished in AML patients. HPGD that encodes 15-PGDH has been proposed
to act as a tumor suppressor gene that is lost in pituitary adenomas [45].
The metabolic data presented here point to the loss or impairment of
this potential tumor suppressor pathway in AML. Finally, PGJ2 is formed
rapidly and spontaneously fromPGD2 inmast cells and has antiprolifer-
ative potency [23,46]. AML plasma had markedly reduced concentra-
tions of PGJ2, particularly in high BM blast, high peripheral blast and
unfavorable prognosis risk patients. The extent to which this prosta-
glandin and its metabolite Δ12-PGJ2 contribute to the clinical picture
in certain AML patients is currently unknown.
Despite the profound alteration in the plasma lipidome in AML, a
number of important and related questions remain. First, is the changed
lipid proﬁle in AML contributing to the pathobiology or is AML itself
contributing to the altered plasma lipidome? The answer to this may
come from the observation that our patient group, albeit small, was
highly genetically heterogeneous. Moreover, some patients had a high
proportion and others a low proportion of blasts. Yet, many of the re-
ported lipidomic changes were universal to AML, suggesting that even
a small number of blasts could disturb the plasma lipidome. In contrast,
other lipid alterations, particularly among the eicosanoids, were related
to disease severity and prognostic risk. Here, the disease may have con-
tributed to the distorted lipid metabolism.
Second, towhat extent doAML blast cells produce the observed lipid
metabolites or lipid metabolizing enzymes? This is partly answered by
the foregoing, in that certain eicosanoids, in particular, were elevated
in patients with the greatest proportion of blasts. Future investigations
will be required to provide deﬁnitive answers through a comparison
of the AML blast lipidomewith that of leukocytes fromhealthy subjects,
where early data already exist [2–4].
Finally, as stated above, disturbances of lipid homeostasis in leuke-
mias were ﬁrst observed from the lowered lipid content of leukemic
cells [2–4]. The data presented here are from lipidomic analyses of
AML and control plasma. The question remains, are these intracellular
and extracellular lipid perturbations related and, if so, by what mecha-
nisms? The relatively recent recognition that membrane ABC
113T. Pabst et al. / BBA Clinical 7 (2017) 105–114transporters were able to transport natural lipids and lipid analogues
[47] has led to further investigation of cellular lipid export by ABC trans-
porters. For example, cholesterol was reported to be transported out of
cells by ABCA1 and that mutations in the ABCA1 gene were responsible
for Tangier disease [47–49]. Furthermore, activity of the multidrug
transporter P-glycoprotein (ABCB1) has been shown to be stimulated
by the presence of cholesterol either extracellularly [50] or in themem-
brane [51] and ABCB1 actively redistributes cholesterol from the cyto-
plasmic side to the exoplasmic side of the membrane [51]. Evidence
has been presented for the cellular export of other lipid entities by a
range of ABC transporters [52]. With regard to AML, cell culture exper-
iments demonstrated that AML cells are able to upregulate through epi-
genetic mechanisms the expression of a number of transporter proteins
[53]. The mRNA expression for ABCA5, ABCB6, ABCC1, and ABCC3 has
recently been reported to be upregulated in cells from 233AML patients
[54]. It is therefore likely that perturbed plasma lipid proﬁles in AML are
related to intracellular changes in circulating AML cells throughmecha-
nisms involving multiple ABC transporters.
In summary, this multiplatform lipidomic investigation of AML has
uncovered a number of metabolic pathways that were both up- and
down-regulated in AML, many of which were previously unknown in
AML. Several of these dysregulated pathways point towards potential
contributing mechanisms in AML pathogenesis. Moreover, some path-
ways mapped to the most severe clinical disease features, including
high BM and peripheral blasts and unfavorable prognostic risks, deter-
mined at diagnosis by cytogenetic and genetic analyses. This ﬁrst
lipidomic study of AML provides a springboard for several new direc-
tions of research into AML and may provide opportunities to identify
novel druggable targets for the treatment of this leukemia that currently
has only a 26% 5-year survival rate.
5. Conclusion
Patientswith AML have a signiﬁcant number of altered plasma lipids
at diagnosis. Components of the lipidome affected include total choles-
terol and fatty acids, fatty acid amides, glycerolipids, phospholipids,
sphingolipids, cholesterol esters, coenzymeQ10, togetherwithmany ei-
cosanoids. In particular, arachidonic acid precursors and eicosanoidme-
tabolites are positively related to disease severity and prognostic
outlook and therefore may be drivers of the disease. Of all lipids deter-
mined in this study, plasma PGF2α at the time of diagnosis may be a
marker for reduced disease severity and prognostic risk. Understanding
perturbations in the AML plasma lipidome may lead to new targets for
drug therapy of AML.
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